Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped an eight-day winning streak.
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...
Gilead Sciences ticked upwards for the eight consecutive session
Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...
FierceBiotech1d
Gilead taps German biotech Tubulis for solid tumor ADC development deal worth up to $465M
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
BioSpace1d
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
Zacks.com on MSN4h
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...
bovnews1h
The GILD Conundrum: Why Gilead Sciences, Inc.’s Stock Is Making Headlines Again
Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...
pharmaphorum1d
Gilead looks beyond Trodelvy with Tubulis alliance
The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...
Gilead, Tubulis Partner To Develop ADC Candidate For Solid Tumor Target
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...
Gilead enters ADC option and license pact with Tubulis, sees dilution
Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...
FiercePharma2h
AstraZeneca's Enhertu and Akeso's bispecifics win national coverage in China as CAR-T therapies miss out again
Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth ...